A window-of-opportunity biomarker study of etodolac in resectable breast cancer

Observational data show that nonsteroidal anti-inflammatory drug (NSAID) use is associated with a lower rate of breast cancer. We evaluated the effect of etodolac, an FDA-approved NSAID reported to inhibit cyclooxygenase (COX) enzymes and the retinoid X receptor alpha (RXR), on rationally identified...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwab, Richard B, Kato, Shumei, Crain, Brian, Pu, Minya, Messer, Karen, Weidner, Noel, Blair, Sarah L, Wallace, Anne M, Carson, Dennis A, Parker, Barbara A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618628/
https://www.ncbi.nlm.nih.gov/pubmed/26275572
http://dx.doi.org/10.1002/cam4.512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618628/
https://www.ncbi.nlm.nih.gov/pubmed/26275572
http://dx.doi.org/10.1002/cam4.512

Ejemplares similares